Stay updated with breaking news from Taphylococcus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cellulitis, a bacterial skin infection, can manifest with symptoms such as swelling, tenderness, pain, and skin dimpling. Commonly targeting the lower extremities, it can become severe if left untreated.
Frequently referred to as staph, Staphylococcus aureus is a type of bacteria that is commonly found on the skin and hair, as well as in the nose and throat of people and animals. In fact, the Centers for Disease Control and Prevention (CDC) reports that about 30% of people carry Staphylococcus aureus in their nose., , , , While most of the time staph does not cause harm to healthy individuals, it has long been recognized as a cause of infections for at risk individuals. These range from m...
MyJournals.org - Science - 'Cheilitis in an atopic dermatitis patient associated with co-infection of Staphylococcus pseudintermedius and Staphylococcus aureus' (BMC Microbiology)
MyJournals.org - Science - 'Percutaneous pedicle screw fixation was effective for bone regeneration after a huge vertebral defect due to intractable pyogenic spondylitis caused by methicillin-resistant Staphylococcus aureus: a case report' (Journal of Medical Case Reports)
Staphylococcus aureus is a type of bacteria that has long been recognized as a cause of disease. Frequently referred to as staph, it is commonly found on the skin and hair, as well as in the nose and throat of people and animals. The Centers for Disease Control and Prevention (CDC) even reports that about 30% of people carry Staphylococcus aureus in their nose., , , , Most of the time, staph does not cause harm to healthy individuals. However, sometimes it can cause infections ranging fro...
- Research shows XZ.700* could block tumor promoting effects of S. aureus on malignant T cells, potentially delaying tumor progression. Findings strengthen ...
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, announces the completion of the Pre-IND discussions